Oakville, Ontario–(Newsfile Corp. – August 9, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (“Cardiol“ or the “Company“), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory...
Oakville, Ontario–(Newsfile Corp. – July 7, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (“Cardiol“ or the “Company“), a clinical-stage biotechnology company focused...
Oakville, Ontario–(Newsfile Corp. – June 30, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (“Cardiol“ or the “Company“), a clinical-stage biotechnology company focused...
Oakville, Ontario–(Newsfile Corp. – June 28, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (“Cardiol“ or the “Company“), a clinical-stage biotechnology company focused...
Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease...
Results expected to support the Company’s plans to file an IND application with the FDA for a Phase II international trial in acute myocarditis Oakville, Ontario–(Newsfile...
Oakville, Ontario–(Newsfile Corp. – April 1, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (“Cardiol“ or the “Company“), a clinical-stage biotechnology company focused...
Oakville, Ontario–(Newsfile Corp. – March 30, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (“Cardiol“ or the “Company“), a clinical-stage biotechnology company focused...
Oakville, Ontario–(Newsfile Corp. – March 2, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) (“Cardiol” or the “Company“), a clinical-stage biotechnology company focused...
Oakville, Ontario–(Newsfile Corp. – January 7, 2021) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company“), a clinical-stage biotechnology company focused on developing...